CLINICAL_TRIALS
trial_result
· 2022-09-19
Clinical Trial Update: Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017) [Phase 3]
Summary
Phase 3 results evaluate safety and efficacy of switching to a Doravirine/Islatravir regimen in participants with HIV-1.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Merck Sharp & Dohme LLC | Conditions: HIV Infection | Phase 3 | Status: COMPLETED | Results posted: 2022-09-19